Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
266.25
-2.7 (-1%)
Market Cap: 34.34 Bil
Enterprise Value: 33.21 Bil
PE Ratio: 0
PB Ratio: 1,065.00
GF Score: 78/100 
Alnylam Pharmaceuticals Inc at Stifel Virtual Healthcare Conference Transcript
Nov 16, 2020 / 07:00PM GMT
Release Date Price:
$131.05
(-3.29%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Awesome. Great. Thanks very much everybody, and thanks for everyone who's been tuning in all day. Happy to be here with the CEO of Alnylam, John Maraganore, from your apartment in Boston. Is that what we're looking at right now?
John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director
We're in Boston in my apartment. That's right. You got it.
Paul Andrew Matteis;John M. Maraganore
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst;Alnylam Pharmaceuticals, Inc. - CEO &
All right. Awesome. Well, thanks so much for joining, John. I really appreciate it as always.
Everyone knows Alnylam well, but do you want to just kind of set the stage and maybe just quickly recap your recent quarter, program updates and then we can get into specifics?
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers